Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 33369355

Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
N Engl J Med
Publication date
2020 Dec 24
First author
Wei AH

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Nat Rev Clin Oncol. 2021 Mar;18(3):132. doi: 10.1038/s41571-021-00475-3.
    note
    Source null
    related pmid
    33462426
    relationship
    Comment in
  2. citation
    N Engl J Med. 2021 Apr 1;384(13):e51. doi: 10.1056/NEJMc2101283.
    note
    Source null
    related pmid
    33789022
    relationship
    Comment in

Authors and identifiers

  1. name
    Wei AH
    type
    Author
  2. name
    Döhner H
    type
    Author
  3. name
    Pocock C
    type
    Author
  4. name
    Montesinos P
    type
    Author
  5. name
    Afanasyev B
    type
    Author
  6. name
    Dombret H
    type
    Author
  7. name
    Ravandi F
    type
    Author
  8. name
    Sayar H
    type
    Author
  9. name
    Jang JH
    type
    Author
  10. name
    Porkka K
    type
    Author
  11. name
    Selleslag D
    type
    Author
  12. name
    Sandhu I
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Wei AH
    type
    Author
  2. name
    Döhner H
    type
    Author
  3. name
    Pocock C
    type
    Author
  4. name
    Montesinos P
    type
    Author
  5. name
    Afanasyev B
    type
    Author
  6. name
    Dombret H
    type
    Author
  7. name
    Ravandi F
    type
    Author
  8. name
    Sayar H
    type
    Author
  9. name
    Jang JH
    type
    Author
  10. name
    Porkka K
    type
    Author
  11. name
    Selleslag D
    type
    Author
  12. name
    Sandhu I
    type
    Author
bibliography ids
  1. nci-bib-64dba1183be44438cd45c0dc
book metadata
content sha256
4ae51a7df5b345f205104c926c90cb3c8f85c94a96fd133c9c88718e2eb8fa2b
document type
citation
dois
  1. 10.1056/NEJMoa2004444
electronic publication date
display
Source null
precision
missing
year
Source null
evidence scope
bibliographic_metadata_only
id
pubmed:33369355
immutable id
pubmed:33369355@4ae51a7df5b345f205104c926c90cb3c8f85c94a96fd133c9c88718e2eb8fa2b
journal
abbreviation
N Engl J Med
issn electronic
1533-4406
issn print
0028-4793
issue
26
name
The New England journal of medicine
nlm unique id
0255562
pages
2526-2537
volume
383
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Nat Rev Clin Oncol. 2021 Mar;18(3):132. doi: 10.1038/s41571-021-00475-3.
    note
    Source null
    related pmid
    33462426
    relationship
    Comment in
  2. citation
    N Engl J Med. 2021 Apr 1;384(13):e51. doi: 10.1056/NEJMc2101283.
    note
    Source null
    related pmid
    33789022
    relationship
    Comment in
outcomes validated
false
pmid
33369355
provenance
batch id
9bca82d1bba2b27adc79
provider
NCBI PubMed ESummary
record sha256
f6136dbc84d0166289367b8c35a8b657219f1b937b3cfa36087c79e5347b40c4
response sha256
c8a4853c65a45038af15f5ade3970763bfa121cf5c68bafcc52c3a06860d0211
retrieved at
2026-09-09T23:47:56.131551+00:00
publication date
display
2020 Dec 24
precision
day
year
2020
publication types
  1. Clinical Trial, Phase III
  2. Journal Article
  3. Multicenter Study
  4. Randomized Controlled Trial
  5. Research Support, Non-U.S. Gov't
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/33369355/
title
Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission.

Preserved source evidence · Not medical advice